Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901482 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Satsuma Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,201
- Enrollment target
NCT03901482 is a Phase 3 study that has completed, run by Satsuma Pharmaceuticals. The registered enrollment target is 1,201 participants.
The verdict
NCT03901482, a Phase 3 study, has completed, sponsored by Satsuma Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,201 participants
- Enrollment target
Study Summary
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine
Interventions
- DRUG Placebos
- DRUG Dihydroergotamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,201 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03901482
The ClinicalTrials.gov registry entry for NCT03901482 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Satsuma Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03901482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03901482 about?
NCT03901482 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine". Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine
What is the current status of trial NCT03901482?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,201 participants. The study started on 2019-06-24. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT03901482?
The interventions under investigation include: Placebos (DRUG), Dihydroergotamine (DRUG).
Who is sponsoring clinical trial NCT03901482?
This trial is sponsored by Satsuma Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.